DSIP is not listed as a scheduled controlled substance under the international drug-control conventions or under the major national scheduling systems
"As with many emerging medical interventions, athletes, coaches, agents, physicians and performance staff are asking questions about their potential benefits and risks." The growing interest has caught the attention of watchdogs, too
Many clients benefit from bi-weekly or monthly injections for maintenance, while those with significant deficiencies may start with weekly treatments
Based on these data, experts recommend initiating studies with a conservative daily dosage of 0.5mg and before increasing to up to 1mg and 2mg daily, depending on the subject's tolerance and response
That makes it a useful option if you want a more joint-friendly way to build strength and conditioning, and many people find they can get a solid session done in 1020 minutes
Areas Without Adequate Human Evidence Cardiovascular safety Neurological and psychiatric effects Liver and kidney safety Effects on blood glucose in humans Effects on methylation pathways Genotoxicity Carcinogenicity Reproductive and developmental toxicity Use during pregnancy or breastfeeding Interactions with prescription medicines Interactions with supplements or research compounds Long-term exposure Product-Quality Risks Incorrect quinolinium compound Wrong substitution position Incorrect counterion Incorrect active-content calculation Residual starting materials Residual solvents Degradation products Heavy-metal or inorganic contamination Mismatched certificate of analysis Uncontrolled storage and transport Absence of published harm is not proof of safety A compound without routine regulated human exposure may generate very few formal safety reports simply because there is no organised pharmacovigilance system
